Lenalidomida Aurovitas (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4 E3 ubiquitin ligase complex, altering the degradation of specific transcription factors. This leads to reduced angiogenesis, modulation of cytokine release, activation of immune cells, and induction of apoptosis in malignant plasma cells.

The prescribed dose of lenalidomide is individualized by the treating physician based on the specific indication, patient characteristics, and laboratory parameters. Dosing regimens may differ for multiple myeloma versus myelodysplastic syndromes, and adjustments are made according to renal function and tolerability.

Lenalidomide is classified as potentially teratogenic and is contraindicated during pregnancy. Women of child‑bearing potential must use effective contraception. Safety data for breastfeeding are insufficient, so breastfeeding is not recommended while receiving the medication.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenalidomide shares the same immunomodulatory class as thalidomide and pomalidomide but generally offers a more favorable safety profile, especially regarding peripheral neuropathy. Pomalidomide is often reserved for patients who have progressed after lenalidomide therapy. Choice of agent depends on disease stage, prior treatment, and individual tolerability.

Store the product at below 25°C in its original container, protecting it from moisture and light. Keep the medication out of reach of children and avoid exposing it to extreme temperatures or humidity, which could affect its stability.

Lenalidomida Aurovitas is taken orally, usually once daily, with or without food as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless otherwise instructed.

The most serious risks include venous thromboembolism, severe neutropenia or infections, severe thrombocytopenia with bleeding, secondary primary malignancies, and serious skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for signs of these events and seek immediate medical attention if they occur.

Lenalidomida Aurovitas should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or its excipients, patients with uncontrolled severe renal impairment without dose adjustment, and those with a history of severe thromboembolic events unless appropriate prophylaxis is in place.